Purpose: To compare the safety, efficacy, and predictability of laser in situ keratomileusis treatments at 1 year postprocedure using a novel geometric ray tracing algorithm with outcomes of treatments using wavefront-optimized, wavefront-guided, and topography-guided ablation profiles of an excimer laser (WaveLight GmbH, Erlangen, Germany; Alcon Laboratories, Fort Worth, TX, USA).
Setting: Wellington Eye Clinic, Dublin, Ireland.
Design: Retrospective comparative case series.
Methods: Eyes having a preoperative myopic spherical equivalent refractive error >4.00 D and/or astigmatism between 2.00-6.00 D resulting in a spherical equivalent power greater than -4.00 D received laser in situ keratomileusis treatments using a ray tracing algorithm. Refractive outcomes were analyzed postoperatively at 6 and 12 months and were compared to outcomes of wavefront-optimized, wavefront-guided, and topography-guided treatments in eyes with the same pretreatment refractive range.
Results: Forty-seven eyes of 26 patients were treated using the ray tracing algorithm. At 12 months postprocedure, uncorrected visual acuity was better than the preoperative best-corrected visual acuity in this group. The percentage of eyes achieving an uncorrected visual acuity or best-corrected visual acuity ≥20/20 significantly exceeded the rates achieved in the wavefront-optimized and topography-guided groups. A greater percentage of eyes achieved an uncorrected visual acuity ≥20/20 and ≥20/16 in the wavefront-guided group, but no eyes in the wavefront-guided group had an uncorrected visual acuity ≥20/12.5 in comparison to 9.5% of eyes in the ray tracing group.
Conclusion: This study provides further evidence of the safety, efficacy, and predictability of laser in situ keratomileusis outcomes using an optical ray tracing algorithm to treat moderate to high myopic astigmatism and shows that good results are sustained through 1 year.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686246 | PMC |
| http://dx.doi.org/10.2147/OPTH.S44720 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased reactive astrocytes and NLRC4-mediated neuronal pyroptosis in advanced visual structures contralateral to the optic nerve crush eye in mice.
Exp Eye Res
January 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic center, Sun Yat-sen University, Guangzhou 510000, Guangdong, China. Electronic address:
Currently, research on optic nerve injury predominantly focuses on the retina and optic nerve, but emerging evidence suggests that optic nerve injury also affects advanced visual structures like the superior colliculus (SC) and primary visual cortex (V1 region). However, the exact mechanisms have not been fully explored. This study aims to investigate the characteristics and mechanisms of pathology in the SC and V1 region after optic nerve crush (ONC) to deepen our understanding of the central mechanism of visual injury.
View Article and Find Full Text PDFOutcomes and safety of Descemet's membrane endothelial keratoplasty (DMEK) as a surgical treatment for corneal endothelial dysfunction: A multicenter study.
J Fr Ophtalmol
January 2025
Service d'ophtalmologie, hôpital La Timone, 264, rue Saint-Pierre, 13005 Marseille, France.
Purpose: To analyze the outcomes and frequency of complications after Descemet's membrane endothelial keratoplasty (DMEK) and evaluate the parameters associated with the occurrence of these complications.
Methods: A multicenter retrospective study of 143 DMEK procedures performed consecutively by five surgeons between June 2018 and March 2021 was performed. Surgeon-specific surgical and graft characteristics were also assessed.
Subthreshold nanosecond laser therapy for chronic central serous chorioretinopathy: A prospective study.
J Fr Ophtalmol
January 2025
Department of Ophthalmology, Saarland University Medical Center UKS, Homburg/Saar, Germany.
Purpose: To investigate the morphologic and functional outcomes of nanosecond subthreshold (ST) laser treatment for patients with chronic central serous chorioretinopathy (CSC).
Methods: In this prospective study, 44 patients were treated with the ST nanosecond laser with a follow-up period of 12 months. All target variables were measured at 1, 3, 6 and 12 months after the first laser treatment.
Ruthenium-106 brachytherapy and central uveal melanoma.
Int Ophthalmol
January 2025
Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
Purpose: Uveal melanoma (UM) is the most common primary ocular malignancy. The size and location of the tumor are decisive for brachytherapy with the β-emitting ruthenium-106 (Ru-106) plaque. The treatment of juxtapapillary and juxtafoveolar UM may be challenging because of the proximity or involvement of the macula and optic nerve and high recurrence rates.
View Article and Find Full Text PDFRetrospective observational cohort study of premature neonates screened for ROP with 7 years of follow-up assessing the visual outcomes and adequacy of preschool visual screening.
BMJ Open Ophthalmol
December 2024
Ophthalmology, Royal Hospital for Children, Glasgow, UK.
Background: Very premature infants screened for retinopathy of prematurity (ROP) that do not develop ROP still experience serious visual developmental challenges, and while it is recommended that all children in the UK are offered preschool visual screening, we aimed to explore whether this vulnerable group requires dedicated follow-up.
Methods: We performed a real-world retrospective observational cohort study of children previously screened for ROP in NHS Greater Glasgow and Clyde (Scotland) between 2013 and 2015. We excluded those with any severity of ROP identified during screening.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!